Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1128-1135

  Levitt, Jonathan M ^a   Yamashita, Hideyuki ^a   Jian, Weiguo ^a   Lerner, Seth P ^a   Sonpavde, Guru ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CISPLATIN; DASATINIB; KI 67 ANTIGEN; PLACEBO; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR XENOGRAFT; UROTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TISSUE ARRAY ANALYSIS; UP-REGULATION; UROLOGIC NEOPLASMS; UROTHELIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952174698     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0096     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077
3. Sonpavde G, Galsky MD, Hutson TE. Current optimal chemotherapy for advanced urothelial cancer. Expert Rev Anticancer Ther 2008;8: 51-61.
4. Sonpavde G, Lerner SP. Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park) 2007;21:1673-81; discussion 1686-8, 1691, 1694.
5. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008;8:427-432
6. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541 (Pubitemid 43882349)
7. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189
8. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-3333
9. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548 (Pubitemid 43927102)
10. Johnson FM, Saigal B, Talpaz M, Donato MJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932 (Pubitemid 41428750)
11. Ceppi P, Papotti M, Monica V, et al. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009;8:3066-3074
12. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007;6:1962-1972 (Pubitemid 47052486)
13. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-972
14. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-2808
15. Masumoto N, Nakano S, Fujishima H, et al. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 1999;80:731-737 (Pubitemid 29066286)
16. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005;4:217-224 (Pubitemid 40340201)
17. George JA, Chen T, Taylor CC. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 2005;65:10381-10388 (Pubitemid 41743731)
18. Konecny GE, Glas R, Dering J, et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009;101: 1699-1708
19. Yamamoto N, Mammadova G, Song RX, et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serumindependent survival of human bladder carcinoma cells. J Cell Sci 2006;119:4623-4633 (Pubitemid 44964259)
20. Chiang GJ, Billmeyer BR, Canes D, et al. The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU Int 2005;96:416-422 (Pubitemid 41097693)
21. Fanning P, Bulovas K, Saini KS, et al. Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res 1992;52: 1457-1462
22. Rasband WS. NIH, Bethesda MD, http://rsb.info.nih.gov/ij/.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
24. Harris JC, Gilliam AD, McKenzie AJ, et al. The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res 2004;64:5624-5631 (Pubitemid 39095558)
25. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5:3014-3022 (Pubitemid 46092042)
26. Luo FR, Barrett YC, Yang Z, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62:1065-1074
27. Wu Y, Moissoglu K, Wang H, et al. Src phosphorylation of RhoG-DI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A 2009;106:5807-5812
28. Kopetz S, Lesslie DP, Dallas NA, et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69: 3842-3849
29. Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009;101:38-47.
30. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007;104:13283-13288 (Pubitemid 47293937)
31. Araujo JC, Poblenz A, Corn P, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 2009;8:2153-2159 Epub ahead of print.
32. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-8. Epub ahead of print 2009 Nov 17.